Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients

Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn and Jeremie Calais
Journal of Nuclear Medicine August 2020, 61 (8) 1171-1177; DOI: https://doi.org/10.2967/jnumed.119.236786
Catherine Meyer
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magnus Dahlbom
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Lindner
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastien Vauclin
4DOSIsoft SA, Cachan, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Mona
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Slavik
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
6Institute of Urologic Oncology, UCLA, Los Angeles, California
7Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
7Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and
8Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
6Institute of Urologic Oncology, UCLA, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 8 1171-1177
DOI 
https://doi.org/10.2967/jnumed.119.236786
PubMed 
31836685

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication September 18, 2019
  • Accepted for publication December 2, 2019
  • Published online August 3, 2020.

Article Versions

  • previous version (December 13, 2019 - 13:35).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Catherine Meyer1,2,
  2. Magnus Dahlbom1,2,
  3. Thomas Lindner3,
  4. Sebastien Vauclin4,
  5. Christine Mona2,
  6. Roger Slavik1,2,5,
  7. Johannes Czernin2,6,7,
  8. Uwe Haberkorn3,7,8 and
  9. Jeremie Calais1,2,5,6
  1. 1Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, California
  2. 2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California
  3. 3Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
  4. 4DOSIsoft SA, Cachan, France
  5. 5Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California
  6. 6Institute of Urologic Oncology, UCLA, Los Angeles, California
  7. 7Clinical Cooperation Unit Nuclear Medicine, DKFZ Heidelberg, Heidelberg, Germany; and
  8. 8Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
  1. For correspondence or reprints contact: Jeremie Calais, Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 200 Medical Pl., Suite B114-61, Los Angeles, CA 90095. E-mail: jcalais{at}mednet.ucla.edu
View Full Text

Statistics from Altmetric.com

Cited By...

  • 114 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer
    Haojun Chen, Yizhen Pang, Jingxun Wu, Liang Zhao, Bing Hao, Jing Wu, Jihong Wei, Siming Wu, Long Zhao, Zuoming Luo, Xuehua Lin, Chengrong Xie, Long Sun, Qin Lin, Hua Wu
    European Journal of Nuclear Medicine and Molecular Imaging 2020 47 8
  • FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
    Frederik L. Giesel, Sebastian Adeberg, Mustafa Syed, Thomas Lindner, Luis David Jiménez-Franco, Eleni Mavriopoulou, Fabian Staudinger, Eric Tonndorf-Martini, Sebastian Regnery, Stefan Rieken, Rami El Shafie, Manuel Röhrich, Paul Flechsig, Andreas Kluge, Annette Altmann, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil
    Journal of Nuclear Medicine 2021 62 2
  • The Latest Developments in Imaging of Fibroblast Activation Protein
    Annette Altmann, Uwe Haberkorn, Jens Siveke
    Journal of Nuclear Medicine 2021 62 2
  • Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients
    Frederik L. Giesel, Clemens Kratochwil, Joel Schlittenhardt, Katharina Dendl, Matthias Eiber, Fabian Staudinger, Lukas Kessler, Wolfgang P. Fendler, Thomas Lindner, Stefan A. Koerber, Jens Cardinale, David Sennung, Manuel Roehrich, Juergen Debus, Mike Sathekge, Uwe Haberkorn, Jeremie Calais, Sebastian Serfling, Andreas L. Buck
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 13
  • Fibroblast Activation Protein–Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
    Yaping Luo, Qingqing Pan, Huaxia Yang, Linyi Peng, Wen Zhang, Fang Li
    Journal of Nuclear Medicine 2021 62 2
  • 68Ga-FAPI-PET/CT in patients with various gynecological malignancies
    Katharina Dendl, Stefan A. Koerber, Rebecca Finck, Kgomotso M. G. Mokoala, Fabian Staudinger, Lisa Schillings, Ulrike Heger, Manuel Röhrich, Clemens Kratochwil, Mike Sathekge, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Frederik L. Giesel
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 12
  • Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers
    Sanjana Ballal, Madhav Prasad Yadav, Euy Sung Moon, Vasko S. Kramer, Frank Roesch, Samta Kumari, Madhavi Tripathi, Sreedharan Thankarajan ArunRaj, Sulochana Sarswat, Chandrasekhar Bal
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 6
  • FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
    Rodney J. Hicks, Peter J. Roselt, Kumarswamy G. Kallur, Richard W. Tothill, Linda Mileshkin
    Journal of Nuclear Medicine 2021 62 3
  • Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model
    Yuwei Liu, Tadashi Watabe, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Sadahiro Naka, Kazuhiro Ooe, Atsushi Toyoshima, Kojiro Nagata, Uwe Haberkorn, Clemens Kratochwil, Atsushi Shinohara, Jun Hatazawa, Frederik Giesel
    European Journal of Nuclear Medicine and Molecular Imaging 2022 49 3
  • Fibroblast Activation Protein Inhibitor PET/CT
    Punit Sharma, Shashank Shekhar Singh, Shankaramurthy Gayana
    Clinical Nuclear Medicine 2021 46 3

Article usage

Article usage: December 2019 to October 2023

AbstractFullPdf
Dec 2019502087
Jan 20203660100
Feb 2020283083
Mar 2020319074
Apr 2020174031
May 2020160047
Jun 2020148080
Jul 20201760133
Aug 2020127851234
Sep 20205064699
Oct 20203393076
Nov 20203423088
Dec 20202812861
Jan 20214495274
Feb 2021181130106
Mar 2021139204188
Apr 2021117176159
May 202183172148
Jun 202192136115
Jul 2021129134101
Aug 202186152137
Sep 2021113190192
Oct 202178180187
Nov 202165152188
Dec 202144190161
Jan 202263139124
Feb 202254127126
Mar 202252151158
Apr 202246133118
May 202276138149
Jun 20225719794
Jul 202253198109
Aug 20223411283
Sep 202238134106
Oct 202237113103
Nov 20222913994
Dec 2022308059
Jan 20233611672
Feb 20235012793
Mar 20234016394
Apr 2023308698
May 20232914192
Jun 20233823751
Jul 20232527383
Aug 20232942580
Sep 20232837077
Oct 202336472119
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (8)
Journal of Nuclear Medicine
Vol. 61, Issue 8
August 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn, Jeremie Calais
Journal of Nuclear Medicine Aug 2020, 61 (8) 1171-1177; DOI: 10.2967/jnumed.119.236786

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
Catherine Meyer, Magnus Dahlbom, Thomas Lindner, Sebastien Vauclin, Christine Mona, Roger Slavik, Johannes Czernin, Uwe Haberkorn, Jeremie Calais
Journal of Nuclear Medicine Aug 2020, 61 (8) 1171-1177; DOI: 10.2967/jnumed.119.236786
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications
  • FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
  • The Latest Developments in Imaging of Fibroblast Activation Protein
  • Fibroblast Activation Protein-Targeted PET/CT with 68Ga-FAPI for Imaging IgG4-Related Disease: Comparison to 18F-FDG PET/CT
  • FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
  • Google Scholar

More in this TOC Section

Theranostics

  • Evaluation of residual on syringe pump delivery system for PLUVICTO™ (Lu-177 vipivotide tetraxetan)
  • The effect of Lu-177 Pluvicto therapy treatments on PSA levels
  • Imaging response assessment with post 177Lu-PSMA-617 therapy SPECT-CT in metastatic castrate resistant prostate cancer: Adding value with a technologist driven post-processing workflow
Show more Theranostics

Clinical

  • Evaluation of residual on syringe pump delivery system for PLUVICTO™ (Lu-177 vipivotide tetraxetan)
  • The effect of Lu-177 Pluvicto therapy treatments on PSA levels
  • Imaging response assessment with post 177Lu-PSMA-617 therapy SPECT-CT in metastatic castrate resistant prostate cancer: Adding value with a technologist driven post-processing workflow
Show more Clinical

Similar Articles

Keywords

  • FAPI
  • PET/CT
  • 68Ga
  • dosimetry
  • biodistribution
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire